

LETTER

CXCLI3 Is a Biomarker of Anti-Leucine-Rich Glioma-Inactivated Protein I Encephalitis Patients [Letter]

This article was published in the following Dove Press journal: Neuropsychiatric Disease and Treatment

Mingyu Wei¹ Zuowei Duan²

¹Medical College of Yangzhou University, Yangzhou 225000, Jiangsu, People's Republic of China; ²Department of Neurology, The Affiliated Hospital of Yangzhou University, Yangzhou 225000, Jiangsu, People's Republic of China

Dear editor

We recently read the original report by Lin and colleagues with great interest. In this study, the authors concluded that both serum and cerebrospinal fluid (CSF) levels of CXCL13, a B cell chemotactic factor, were significantly higher in patients with anti-leucine-rich glioma-inactivated protein 1 (anti-LGI1) encephalitis compared to non-inflammatory neurologic disorder control groups. However, we have some concerns about the interpretation of their data.

Previous research has shown that patients with anti-LGI1 encephalitis do not show significant cytokine and chemokine alterations in the CSF.² However, the authors inferred an opposite conclusion that both serum and CSF levels of CXCL13 were significantly higher in patients with anti-LGI1 encephalitis versus non-inflammatory neurologic disorder control groups. Specifically, the dispersion around the mean serum level of CXCL13 (36.32 \pm 34.71 pg/mL) was much larger in this study, compared to other cytokine and chemokine levels that remained unchanged between groups. We believe that the statistical significance of this major finding of the study may be over-estimated, as the authors did not use a Bonferroni correction or a multifactorial analysis of variance. Furthermore, the blood-brain barrier permeability as measured by albumin index (i.e., the albumin level ratio, CSF/serum)³ was not accounted for in this study. Therefore, it is unclear if serum or CSF CXCL13 plays a more important role in the pathogenesis of anti-LGI1 encephalitis. Additionally, increased circulating CXCL13 levels can also be found in other autoimmune diseases such as rheumatoid arthritis.⁴ Thus, the specificity of CXCL13 as a biomarker for anti-LGI1 encephalitis, may not be as high as the authors would predict, due to potential coexistence of anti-LGI1 encephalitis and other autoimmune diseases. We recommend that these potential confounders be noted by the editors to ensure that other researchers are similarly critical in their interpretation of these data.

Disclosure

The authors report no conflicts of interest in this communication.

References

Correspondence: Zuowei Duan Email jydzw061344@163.com

 Lin Y, Yang X, Lv J, Liu XW, Wang SJ. CXCL13 is a biomarker of anti-leucine-rich glioma-inactivated protein 1 encephalitis patients. *Neuropsychiatr Dis Treat*. 2019;15:2909–2915. doi:10.2147/NDT.S222258 Wei and Duan Dovepress

- Byun JI, Lee ST, Moon J, et al. Distinct intrathecal interleukin-17/ interleukin-6 activation in anti-N-methyl-d-aspartate receptor encephalitis. J Neuroimmunol. 2016;297:141–147. doi:10.1016/j. jneuroim.2016.05.023
- 3. Wang Y, Zhu M, Liu C, et al. Blood brain barrier permeability could be a biomarker to predict severity of neuromyelitis optica spectrum disorders: a retrospective analysis. *Front Neurol.* 2018;9:648. doi:10.3389/fneur.2018.00648
- Bao Y, Wang J, Dai Z, et al. Increased circulating CXCL13 levels in systemic lupus erythematosus and rheumatoid arthritis: a meta-analysis. Clin Rheumatol. 2019:1–10 doi:10.1007/s10067-019-04775 -

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Neuropsychiatric Disease and Treatment 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Neuropsychiatric Disease and Treatment editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Neuropsychiatric Disease and Treatment

Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peerreviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the 'PsycINFO' database and CAS, and is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

 $\textbf{Submit your manuscript here:} \ \texttt{https://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal} \\$

Dovepress